Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343881 | 1.00 | ADORA3 (0.46) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| SCHEMBL343882 | 1.00 | ADORA3 (0.46) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| SCHEMBL20268268 | 1.00 | ADORA3 (0.46) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL298755 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL15804 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL4110068 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL6748954 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL12763613 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL20138477 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 | |
| Inosine SCHEMBL2229394 | 0.77 | SLC29A1 (0.75) | ADORA3ADORA2ASMN1; SMN2SLC29A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085691-A1 | TRANS-SPLICING NUCLEIC ACID MOLECULES AND METHODS OF USE | TACIT THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118974253-A | Therapeutic application of CRISPR V-type system | 卡里布生物科学公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118202051-A | RNA editing by recruiting spliceosome components | 泰思特治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4359539-A1 | OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS | University Of Massachusetts (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023201270-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2022271786-A1 | OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS | UNIVERSITY OF MASSACHUSETTS (US) | 2022-12-29 | — | — | WO | disclosed |